An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas

Akane Yamamichi, Toshihiro Kasama, Fumiharu Ohka, Hiromichi Suzuki, Akira Kato, Kazuya Motomura, Masaki Hirano, Melissa Ranjit, Lushun Chalise, Michihiro Kurimoto, Goro Kondo, Kosuke Aoki, Noritada Kaji, Manabu Tokeshi, Toshio Matsubara, Takeshi Senga, Mika K. Kaneko, Hidenori Suzuki, Masahito Hara, Toshihiko Wakabayashi & 3 others Yoshinobu Baba, Yukinari Kato, Atsushi Natsume

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.

Original languageEnglish
Pages (from-to)618-625
Number of pages8
JournalScience and Technology of Advanced Materials
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 1 2016
Externally publishedYes

Fingerprint

Isocitrate Dehydrogenase
Genes
Tumors
Neurology
Brain
Tissue
Ports and harbors
Oxidoreductases
Microchannels
Antibodies
Polymers
Cells
Health
Proteins

All Science Journal Classification (ASJC) codes

  • Materials Science(all)

Cite this

An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. / Yamamichi, Akane; Kasama, Toshihiro; Ohka, Fumiharu; Suzuki, Hiromichi; Kato, Akira; Motomura, Kazuya; Hirano, Masaki; Ranjit, Melissa; Chalise, Lushun; Kurimoto, Michihiro; Kondo, Goro; Aoki, Kosuke; Kaji, Noritada; Tokeshi, Manabu; Matsubara, Toshio; Senga, Takeshi; Kaneko, Mika K.; Suzuki, Hidenori; Hara, Masahito; Wakabayashi, Toshihiko; Baba, Yoshinobu; Kato, Yukinari; Natsume, Atsushi.

In: Science and Technology of Advanced Materials, Vol. 17, No. 1, 01.01.2016, p. 618-625.

Research output: Contribution to journalArticle

Yamamichi, A, Kasama, T, Ohka, F, Suzuki, H, Kato, A, Motomura, K, Hirano, M, Ranjit, M, Chalise, L, Kurimoto, M, Kondo, G, Aoki, K, Kaji, N, Tokeshi, M, Matsubara, T, Senga, T, Kaneko, MK, Suzuki, H, Hara, M, Wakabayashi, T, Baba, Y, Kato, Y & Natsume, A 2016, 'An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas', Science and Technology of Advanced Materials, vol. 17, no. 1, pp. 618-625. https://doi.org/10.1080/14686996.2016.1227222
Yamamichi, Akane ; Kasama, Toshihiro ; Ohka, Fumiharu ; Suzuki, Hiromichi ; Kato, Akira ; Motomura, Kazuya ; Hirano, Masaki ; Ranjit, Melissa ; Chalise, Lushun ; Kurimoto, Michihiro ; Kondo, Goro ; Aoki, Kosuke ; Kaji, Noritada ; Tokeshi, Manabu ; Matsubara, Toshio ; Senga, Takeshi ; Kaneko, Mika K. ; Suzuki, Hidenori ; Hara, Masahito ; Wakabayashi, Toshihiko ; Baba, Yoshinobu ; Kato, Yukinari ; Natsume, Atsushi. / An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. In: Science and Technology of Advanced Materials. 2016 ; Vol. 17, No. 1. pp. 618-625.
@article{8c48bf89c72a409aaab6c642fb7061bf,
title = "An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas",
abstract = "World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80{\%} of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90{\%} are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10{\%} content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.",
author = "Akane Yamamichi and Toshihiro Kasama and Fumiharu Ohka and Hiromichi Suzuki and Akira Kato and Kazuya Motomura and Masaki Hirano and Melissa Ranjit and Lushun Chalise and Michihiro Kurimoto and Goro Kondo and Kosuke Aoki and Noritada Kaji and Manabu Tokeshi and Toshio Matsubara and Takeshi Senga and Kaneko, {Mika K.} and Hidenori Suzuki and Masahito Hara and Toshihiko Wakabayashi and Yoshinobu Baba and Yukinari Kato and Atsushi Natsume",
year = "2016",
month = "1",
day = "1",
doi = "10.1080/14686996.2016.1227222",
language = "English",
volume = "17",
pages = "618--625",
journal = "Science and Technology of Advanced Materials",
issn = "1468-6996",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas

AU - Yamamichi, Akane

AU - Kasama, Toshihiro

AU - Ohka, Fumiharu

AU - Suzuki, Hiromichi

AU - Kato, Akira

AU - Motomura, Kazuya

AU - Hirano, Masaki

AU - Ranjit, Melissa

AU - Chalise, Lushun

AU - Kurimoto, Michihiro

AU - Kondo, Goro

AU - Aoki, Kosuke

AU - Kaji, Noritada

AU - Tokeshi, Manabu

AU - Matsubara, Toshio

AU - Senga, Takeshi

AU - Kaneko, Mika K.

AU - Suzuki, Hidenori

AU - Hara, Masahito

AU - Wakabayashi, Toshihiko

AU - Baba, Yoshinobu

AU - Kato, Yukinari

AU - Natsume, Atsushi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.

AB - World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (IDH1), of which 83–90% are found to be the IDH1-R132H mutation. Detection of the IDH1-R132H mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the IDH1-R132H mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the IDH1 status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the IDH1-R132H mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the IDH1-R132H mutation in routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85019134989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019134989&partnerID=8YFLogxK

U2 - 10.1080/14686996.2016.1227222

DO - 10.1080/14686996.2016.1227222

M3 - Article

VL - 17

SP - 618

EP - 625

JO - Science and Technology of Advanced Materials

JF - Science and Technology of Advanced Materials

SN - 1468-6996

IS - 1

ER -